TScan Therapeutics shares jumped 23% in premarket trading after a $30 million registered direct offering. Shares were trading around $3.58. The stock is down about 50% on the year.

Clinical-stage biotechnology company TScan Therapeutics, Inc. (TCRX) Thursday announced that it has entered into a securities ...

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027 ...

Additional information about the reverse stock split can be found in Optinose's Definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC”) on December 12, 2024. The Proxy ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for ...

TScan Therapeutics (TCRX) entered into a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of approximately $30M of pre-funded warrants ...